Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). Issue 6 (June 2022) - Martin-Blondel, Guillaume; Marcelin, Anne-Genevieve; Soulié, Cathia; Kaisaridi, Sofia; Lusivika-Nzinga, Clovis; Dorival, Céline; Nailler, Laura; Boston, Anaïs; Melenotte, Cléa; Gaube, Géraldine; Choquet, Christophe; Liblau, Roland; et al.